Sign inJoin waitlistJoin the waitlist

Tahir Latif

Director, Infusion Services UCMC · University of Cincinnati Medical Center Inc.

Credentials: · · · · · · · ·

History

University of Cincinnati Medical Center Inc.
Present

Hematology and Medical Oncology
Cleveland Clinic Foundation
1999–2002
Internal Medicine
Cleveland Clinic Florida
1996–1999
Allama Iqbal Medical College
1992–1996
Texas Tech University Rawls College of Business Administration (Business

Research

Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib
Leukemia · 2015 · 96 citations
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia
Nature Medicine · 2017 · 89 citations
COVID-19 vaccination and breakthrough infections in patients with cancer
Annals of Oncology · 2022 · 88 citations

Jordan Kharofa
4 papers
Olugbenga Olowokure
4 papers
Abhimanyu Ghose
3 papers · 2 as a fellow
Chris Labaki
3 papers
Gayathri Nagaraj
3 papers
Jeremy Warner
3 papers
MP
Matthew Puc
3 papers
Rana McKay
3 papers
Sameer Patel
3 papers
Stephanie Berg
3 papers
Syed Ahmad
3 papers
Trisha Wise-Draper
3 papers · 1 as a resident

Clinical trials

Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
Principal investigator · Active not recruiting · Phase 2
Tahir Latif
2018–2024
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Site PI · Recruiting · Phase 2
Allogene Therapeutics
2024–2032
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Site PI · Recruiting · Phase 2
Alliance for Clinical Trials in Oncology
2021–2027